Sample rows from Sleep Disorders. Field types are labelled in each column heading.
#	TextID	TextDisease Name	TextCategory	TextPrevalence	TextInheritance Pattern	TextAffected Gene(s)	LocationChromosome Location	TextKey Symptoms	TextTypical Age of Onset	TextDiagnosis Methods	TextAvailable Treatments	TextOrphan Drug Designation	TextICD-10 Code	NumberOMIM Number	TextAffected System	TextDisease Severity	TextLife Expectancy Impact
01	1	Chronic Insomnia Disorder	Insomnia	~6-10% of adults globally meet DSM-5/ICSD-3-TR criteria; ~30% report symptoms (AASM 2023)	Multifactorial (stress, hyperarousal, learned maladaptive associations, genetic predisposition)	Host: polygenic (MEIS1, BTBD9, CACNA1C, AUTS2 GWAS hits)	Multiple loci	Difficulty initiating/maintaining sleep or early-morning awakening >=3 nights/week for >=3 months with daytime impairment	Adults any age; peak 40-60 years	Clinical history per ICSD-3-TR; sleep diary 1-2 weeks; Insomnia Severity Index (ISI); actigraphy; PSG only if comorbid SDB suspected	CBT-I first-line (AASM 2021); FDA-approved: DORAs daridorexant (Quviviq, Jan 2022), suvorexant (Belsomra), lemborexant (Dayvigo); ramelteon (Rozerem); low-dose doxepin (Silenor); eszopiclone (Lunesta), zolpidem (Ambien)	No	F51.01	N/A	Nervous/Sleep-Wake	Moderate	Variable
02	2	Short-Term Insomnia Disorder	Insomnia	~30-40% of adults annually; ~75% resolve within 1 year; 25% progress to chronic (AASM)	Acquired (acute stressor: bereavement, medical illness, travel, work changes)	Host: polygenic predisposition	N/A	Insomnia symptoms <3 months duration, typically linked to identifiable stressor	Any age	Clinical history per ICSD-3-TR; sleep diary; rule out secondary causes	Stimulus control, sleep hygiene, brief CBT-I; short-term hypnotics if severe (zolpidem/Ambien, eszopiclone/Lunesta) limited to 2-4 weeks; treat underlying stressor	No	F51.02	N/A	Nervous/Sleep-Wake	Mild	None
03	3	Other Insomnia Disorder	Insomnia	Rare; residual ICSD-3-TR category for insomnia not meeting chronic/short-term criteria	Variable (atypical presentations, partial symptoms)	Host: variable	N/A	Insomnia complaints not meeting full chronic or short-term criteria	Any age	Clinical history per ICSD-3-TR exclusion criteria	Individualized: CBT-I components, sleep hygiene education, treat contributing factors	No	F51.09	N/A	Nervous/Sleep-Wake	Mild	None
04	4	Psychophysiological Insomnia	Insomnia	Most common chronic insomnia phenotype; ~1-2% of adults (ICSD-3-TR retains as subtype descriptor)	Acquired (conditioned arousal, performance anxiety about sleep)	Host: trait hyperarousal predisposition	N/A	Heightened arousal in bed, sleep effort, reversed sleep at novel locations, rumination about sleep	Adults 20-40 years	Clinical history; sleep diary showing variable sleep; ISI; PSG reveals prolonged latency	CBT-I with stimulus control and sleep restriction (first-line); relaxation training; paradoxical intention; DORAs	No	F51.04	N/A	Nervous/Sleep-Wake	Moderate	None
05	5	Paradoxical Insomnia (Sleep State Misperception)	Insomnia	~5% of chronic insomnia patients; more common in women	Acquired (perceptual mismatch between subjective and objective sleep)	Host: unknown	N/A	Severe subjective insomnia complaints with normal or near-normal objective sleep on PSG/actigraphy	Adults 30-50 years	PSG showing TST >6.5h with subjective complaint of little/no sleep; actigraphy cross-check	CBT-I with sleep education about perception; cognitive restructuring; avoid unnecessary hypnotics	No	F51.03	N/A	Nervous/Sleep-Wake	Moderate	None

Sleep Disorders

About this dataset

Data preview

Explore the sample

There’s more to discover.